Verge Genomics GTM brain

Verge Genomics, now Verge Labs, partners with drug developers using human neuroscience data and AI models for target discovery and clinical trial design.

category

AI neuroscience drug discovery

market profile

  • text: Neuroscience drug developers face translational risk in identifying disease-relevant targets and selecting patients likely to respond.
  • text: Verge has shifted from its own clinical pipeline toward a partner-facing AI and data platform following a failed ALS trial.

personas

  • title: VP neuroscience discovery or translational research
    pains:
    • Animal and cell models may not reflect human neurological disease
    • Needs stronger human evidence to prioritize targets
  • title: Clinical development and biomarker lead
    pains:
    • Heterogeneous patient populations dilute treatment effects
    • Needs defensible biomarkers and patient selection strategies
  • title: Pharma business development leader
    pains:
    • Must judge the value and validation of external data partnerships
    • Needs a scoped collaboration aligned to pipeline milestones

icp

  • text: Pharmaceutical and biotechnology companies developing neuroscience drugs, including rare neurodegenerative and neuromuscular indications.
  • text: Organizations with discovery assets or clinical trials where human target relevance, biomarkers or patient stratification are strategic priorities.

message pillars

  • text: Start from human brain data.
  • text: Use models to reason about patient biology.
  • text: Connect discovery with trial design.
  • text: Support precision neurology development.

objections

  • objection: Will model predictions translate to clinical benefit?
    response: Review external validation, intended use and the lessons of Verge's unsuccessful ALS study; prospective validation remains essential.
  • objection: Is the data relevant to our indication and patient population?
    response: Assess cohort composition, sample provenance and performance for the specific disease and endpoint before committing.
  • objection: Do we need a broad platform partnership for one asset?
    response: The company describes engagements ranging from full discovery campaigns to focused human-relevance assessments.

competitors

  • name: Isomorphic Labs
    why: AI drug discovery company listed as a Verge competitor.
  • name: Insilico Medicine
    why: AI drug discovery platform competing for pharma research collaborations.
  • name: Variant Bio
    why: Uses human genetic data and AI to identify drug discovery opportunities.

influencers

  • name: Alice Zhang
    url: https://www.vergelabs.blog/p/why-were-becoming-verge-labs
    why: Co-founder explains the shift to Verge Labs and its partner platform.

keywords

  • AI neuroscience drug discovery
  • human brain tissue genomics
  • neurodegenerative disease target discovery
  • clinical trial patient stratification
  • neurology biomarkers
  • AI translational research

voice

  • Scientific and ambitious
  • Human-data focused
  • Research-led

signals

  • text: A pharma team is initiating a neuroscience discovery partnership or seeking human validation for a target.
  • text: A neurology clinical program needs biomarkers or patient enrichment to improve trial design.

pricing

model: unknown

motion

sales_led

channels

  • scientific publications
  • industry partnerships
  • press
  • LinkedIn

confidence

high

Founders

  • name: Alice Zhang
    title: Founder/CEO
    role: CEO

Back to YC companies